DEF: Pasithea Therapeutics Proposes Reverse Stock Split to Avoid Nasdaq Delisting

Pasithea Therapeutics Corp. is seeking stockholder approval for a reverse stock split, ranging from 1-for-2 to 1-for-20, to regain compliance with Nasdaq's minimum bid price requirement and avoid potential delisting.

Summary

• Pasithea Therapeutics Corp. is holding its Annual Meeting of Stockholders on September 9, 2026, in a virtual format.
• Key proposals include the election of director nominees, ratification of the independent auditor, and approval of a reverse stock split.
• The company received a notice from Nasdaq on February 20, 2026, for non-compliance with the $1.00 Minimum Bid Price Requirement.
• A reverse stock split, with a ratio between 1-for-2 and 1-for-20, is proposed to increase the stock price and maintain Nasdaq listing.
• The Board of Directors has approved the reverse stock split proposal and recommends a vote in favor.
• Stockholders of record as of July 24, 2026, are entitled to vote.
• The company's closing stock price on July 24, 2026, was $0.455.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development, as the company is seeking a reverse stock split primarily to avoid delisting, indicating underlying financial distress and a lack of market confidence.

Positives

• The company is proactively addressing the Nasdaq minimum bid price requirement to maintain its listing.
• The virtual meeting format aims to increase stockholder participation.
• The Board of Directors is seeking stockholder approval for the reverse stock split, demonstrating a commitment to corporate governance.
• The company has independent directors on its board and committees, adhering to good governance practices.

Negatives

• The company is at risk of delisting from Nasdaq due to failing to meet the $1.00 Minimum Bid Price Requirement.
• The proposed reverse stock split is a measure to avoid delisting, suggesting underlying financial or market performance issues.
• The reverse stock split could potentially decrease the liquidity of the common stock.
• Cash payments will be made in lieu of fractional shares, which may not be ideal for all stockholders.
• The company's stock price was $0.455 as of July 24, 2026, significantly below the Nasdaq minimum requirement.

Risks

• Failure to regain compliance with Nasdaq's Minimum Bid Price Requirement could lead to delisting.
• The reverse stock split may not be successful in increasing the stock price sufficiently or for a sustained period.
• The market price of the common stock could decline further even after the reverse stock split due to factors unrelated to the split.
• The reverse stock split may decrease the liquidity of the common stock and potentially lead to increased transaction costs for stockholders holding odd lots.
• The increased number of authorized but unissued shares after the reverse split could be used to deter a takeover, potentially against the interests of some stockholders.

Future Outlook

The primary forward-looking aspect is the proposed reverse stock split, intended to increase the stock price to meet Nasdaq's minimum bid price requirement and avoid delisting. The Board believes this action is necessary for the company's continued listing and to potentially improve marketability and liquidity.

Management Comments

• The Board strongly believes that the Reverse Split is necessary to maintain our listing on Nasdaq.
• Management and the Board have considered the potential harm to us and our stockholders should Nasdaq delist our Common Stock from trading.
• The Board does not intend for the Reverse Split to be the first step in a series of plans or proposals to effect a going private transaction.

Industry Context

StockSavvy.ai notes that reverse stock splits are often employed by companies facing delisting threats due to low stock prices. While a common tactic to meet exchange requirements, its success in fundamentally improving a company's financial health or market perception is often debated and depends heavily on the underlying business performance and future prospects.

Corporate Governance

Related Party Transactions

• Consulting Agreement with Prof. Lawrence Steinman: Amended effective October 1, 2025, to reduce compensation from $25,000 per quarter to $1.00 per quarter for consulting and advisory services related to clinical and commercial development.

Stakeholder Impact

• Shareholders: Potential for increased stock price if the reverse split is successful, but also risks of decreased liquidity and potential dilution from authorized but unissued shares. Cash payments for fractional shares may impact smaller holders.
• Investors: May be deterred by the need for a reverse split, signaling financial weakness. However, maintaining Nasdaq listing is crucial for broader investor access.
• Creditors/Lenders: Continued Nasdaq listing is generally positive for maintaining access to capital markets.

Next Steps

• Stockholders will vote on the proposals at the Annual Meeting on September 9, 2026.
• If approved, the Board will determine whether to implement the reverse stock split and select the specific ratio.
• If implemented, the Reverse Split Certificate of Amendment will be filed with the Delaware Secretary of State.
• The company will report the voting results in a Form 8-K filing with the SEC.

Key Dates

Recommendation

The filing indicates a critical need to address the Nasdaq minimum bid price requirement, which is a significant negative. However, the proposed reverse stock split, if successful, could prevent delisting, which is a necessary step for the company's survival in its current market. Without a clear path to fundamental business improvement or profitability indicated in this filing, a 'hold' recommendation is prudent, awaiting further developments and evidence of operational turnaround beyond a stock price manipulation tactic.

Keywords

reverse stock split, Nasdaq delisting, proxy statement, annual meeting, stockholder vote, minimum bid price, corporate governance, Pasithea Therapeutics